Sage Therapeutics
It was a busy week for clinical trial announcements. Take a look.
Sage announced the termination of the REDWOOD and RAINFOREST studies of zuranolone, which is being assessed to treat both major depressive disorder and post-partum depression.
The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).
BioSpace looks at five of the top investor companies that support life sciences companies across the industry.
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.
Recently announced topline results from a Phase II study show SAGE-324, Sage Therapeutics’ investigational oral neuroactive steroid GABAA receptor positive allosteric modulator, significantly reduced tremor score in adult patients with essential tremor.
On Wednesday, Sage Therapeutics and Samsung Biologics announced that they had found just that in their new chief executive officers.
Sage and Biogen forged the deal to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder, postpartum depression and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.
Following a setback with its experimental major depressive disorder drug in December, Sage Therapeutics will initiate a corporate restructuring that includes halving its employee headcount in order to focus its resources on the development of its pipeline.
JOBS
IN THE PRESS